LEADER 01044nam--2200349---450- 001 990003287430203316 005 20090702135224.0 035 $a000328743 035 $aUSA01000328743 035 $a(ALEPH)000328743USA01 035 $a000328743 100 $a20090702d1980----km-y0itay50------ba 101 $aeng 102 $aNL 105 $a||||||||001yy 200 1 $aPalladium catalyzed oxidation of hydrocarbons$fPatrick M. Henry 210 $aDordrecht$cD. Reidel Publishing compant$dcopyr. 1980 215 $aXV, 435 p.$d22 cm 225 2 $aCatalysis by metal complexes$v2 410 0$12001$aCatalysis by metal complexes 606 0 $aOssidazione 606 0 $aIdrocarburi 676 $a541.393 700 1$aHENRY,$bPatrick Mark$0605232 801 0$aIT$bsalbc$gISBD 912 $a990003287430203316 951 $a541.395 CMC 2$b5042/CBS$c541.395$d00224278 959 $aBK 969 $aSCI 979 $aRSIAV6$b90$c20090702$lUSA01$h1352 996 $aPalladium catalyzed oxidation of hydrocarbons$91118058 997 $aUNISA LEADER 04633nam 2201177z- 450 001 9910557349503321 005 20220111 035 $a(CKB)5400000000042395 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77076 035 $a(oapen)doab77076 035 $a(EXLCZ)995400000000042395 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aSystemic Autoinflammatory Diseases-Clinical Rheumatic Challenges 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (266 p.) 311 08$a3-0365-2560-2 311 08$a3-0365-2561-0 330 $aAutoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology. 606 $aMedicine$2bicssc 610 $aadult-onset Still's disease 610 $aanakinra 610 $aanti-IL-1 treatment 610 $aarthritis 610 $aASAS classification criteria 610 $aaspiration 610 $aautoimmune 610 $aautoinflammation 610 $aautoinflammatory disease 610 $aautoinflammatory diseases 610 $aautoinflammatory disorder 610 $acanakinumab 610 $aCAPS 610 $aCINCA 610 $aclinical management 610 $acolchicine 610 $acomputed tomography (CT) 610 $acoronavirus 610 $acytokines 610 $adamage index 610 $adiagnostic delay 610 $aDNA damage repair 610 $adysphagia 610 $aedema 610 $aFCAS 610 $afebuxostat 610 $aFMF 610 $agenetic inheritance 610 $agout 610 $ahaemophagocytic lymphohistiocytosis 610 $ahearing loss 610 $ahepatotoxicity 610 $aHounsfield unit 610 $ahuman leukocyte antigen 610 $aIFN-? 610 $aIL-1 inhibitors 610 $aimaging 610 $aimmunoglobulin G4-related orbital disease (IgG4-ROD) 610 $ainflammation 610 $ainflammatory idiopathic myopathy 610 $aInterleukin-1 610 $aJAK inhibitor 610 $amacrophage activation syndrome 610 $amonogenic autoinflammatory syndrome 610 $aMWS 610 $amyositis 610 $an/a 610 $aneoplasms 610 $anew genetic variant 610 $aNGS 610 $aNOMID 610 $aorbital lymphoma (OL) 610 $aPBMCs 610 $apersonalized therapy 610 $apneumonia 610 $aproliferation 610 $aprophylaxis 610 $aproteasome 610 $aproteasome-associated autoinflammatory syndrome 610 $arheumatoid arthritis 610 $aSARS-CoV-2 antibody response 610 $aspondyloarthritis 610 $aSURF 610 $asynovitis 610 $asystemic-onset juvenile idiopathic arthritis 610 $aT lymphocytes 610 $atherapy 610 $aundifferentiated enthesitis and/or arthritis 610 $aurticarial-like rash 610 $a?H2AX 615 7$aMedicine 700 $aFeist$b Eugen$4edt$01330408 702 $aFeist$b Eugen$4oth 906 $aBOOK 912 $a9910557349503321 996 $aSystemic Autoinflammatory Diseases-Clinical Rheumatic Challenges$93039837 997 $aUNINA